Dongqing Lv

2.6k total citations
92 papers, 509 citations indexed

About

Dongqing Lv is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dongqing Lv has authored 92 papers receiving a total of 509 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in Dongqing Lv's work include Lung Cancer Treatments and Mutations (38 papers), Lung Cancer Research Studies (21 papers) and Peptidase Inhibition and Analysis (15 papers). Dongqing Lv is often cited by papers focused on Lung Cancer Treatments and Mutations (38 papers), Lung Cancer Research Studies (21 papers) and Peptidase Inhibition and Analysis (15 papers). Dongqing Lv collaborates with scholars based in China, United States and Australia. Dongqing Lv's co-authors include Haihua Yang, Xiaomai Wu, Minhua Ye, Mo Shen, Xiaofeng Chen, Xiaofeng Chen, Yuping Li, Weijun Ding, Shuangquan Yan and Guixian Wu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Dongqing Lv

75 papers receiving 506 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dongqing Lv China	13	240	225	168	88	60	92	509
Tatsunori Kiriu Japan	13	199 0.8×	186 0.8×	119 0.7×	57 0.6×	17 0.3×	26	460
Tamio Okimoto Japan	15	168 0.7×	203 0.9×	210 1.3×	98 1.1×	84 1.4×	50	643
Yakun Wang China	11	147 0.6×	114 0.5×	78 0.5×	44 0.5×	30 0.5×	27	487
Marius Žemaitis Lithuania	11	208 0.9×	196 0.9×	220 1.3×	95 1.1×	31 0.5×	34	579
Nitika Sharma United States	9	277 1.2×	164 0.7×	109 0.6×	44 0.5×	31 0.5×	18	488
Levent Dizdar Germany	16	242 1.0×	83 0.4×	174 1.0×	99 1.1×	76 1.3×	30	474
Yukihiro Yano Japan	13	253 1.1×	270 1.2×	98 0.6×	46 0.5×	59 1.0×	48	546
Fangfang Liu China	11	87 0.4×	90 0.4×	100 0.6×	106 1.2×	33 0.6×	29	340
Toshihiko Kaneda Japan	12	271 1.1×	249 1.1×	119 0.7×	33 0.4×	62 1.0×	33	458

Countries citing papers authored by Dongqing Lv

Since Specialization

Citations

This map shows the geographic impact of Dongqing Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongqing Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongqing Lv more than expected).

Fields of papers citing papers by Dongqing Lv

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dongqing Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongqing Lv. The network helps show where Dongqing Lv may publish in the future.

Co-authorship network of co-authors of Dongqing Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Dongqing Lv. A scholar is included among the top collaborators of Dongqing Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dongqing Lv. Dongqing Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gu, Qianqian, Li Zhou, Xiaofei Shen, et al.. (2025). Fatal Empyema Thoracis Caused by Nocardia otitidiscaviarum. Infection and Drug Resistance. Volume 18. 669–678. 1 indexed citations

Lv, Dongqing, Qichao Yang, Wenting Zhang, et al.. (2025). Performance analysis and city applicability evaluation of a transcritical CO2 heat pump system integrated with expander-compressor unit subcooling for space heating. Energy. 320. 135293–135293. 5 indexed citations

Xu, Ming, Dongqing Lv, Shuqing Jin, et al.. (2025). Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review. Diabetes Obesity and Metabolism. 27(4). 1693–1707. 1 indexed citations

Wu, Guixian, Jingjing Qu, Jing Zheng, et al.. (2025). Immunotherapy rechallenge after ICI-related pneumonitis in lung cancer patients: a retrospective cohort study. Frontiers in Oncology. 15. 1527690–1527690.

Lv, Jie, Dongqing Lv, Qichao Yang, et al.. (2025). Comparative performance analysis of a self-heat recuperation driven ejector subcooling transcritical CO2 refrigeration systems using different throttling devices. International Journal of Refrigeration. 176. 106–119. 1 indexed citations

Wu, Yi‐Long, Lin Wu, Nan Bi, et al.. (2025). PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. Journal of Hematology & Oncology. 18(1). 111–111.

Zhou, Jianya, et al.. (2024). 665P Real-world effectiveness and safety of first-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: A prospective, multi-center, real-world study in China (FLOURISH Study). Annals of Oncology. 35. S1653–S1654.

Lv, Dongqing, Weineng Feng, Shuyu Liu, et al.. (2024). 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China. Annals of Oncology. 35. S1661–S1661.

Xing, Puyuan, Dongqing Lv, Weineng Feng, et al.. (2024). 677P Comparison of performance of MET amplification detection by FISH, NGS and ddPCR in EGFRm advanced NSCLC patients post first-line osimertinib treatment failure: Analysis from a prospective, multi-center study in China. Annals of Oncology. 35. S1658–S1658.

10.

Yu, Yongfeng, Yan Yu, Yan Zhang, et al.. (2024). Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study.. Journal of Clinical Oncology. 42(16_suppl). 8089–8089. 3 indexed citations

11.

Cheng, Ying, Xiao‐Chen Zhang, Jian Liu, et al.. (2024). YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.. Journal of Clinical Oncology. 42(16_suppl). 3034–3034. 5 indexed citations

12.

Wu, Guixian, Ling Lin, Chao Zhou, et al.. (2024). Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial. BMC Cancer. 24(1). 1182–1182. 2 indexed citations

13.

Lv, Dongqing, et al.. (2024). High-Throughput Sequencing to Investigate the Expression and Potential Role of Differentially Expressed microRNAs in Myocardial Cells after Ischemia-Reperfusion Injury. Frontiers in Bioscience-Landmark. 29(1). 38–38. 1 indexed citations

14.

Wang, Jie, Zhijie Wang, Lin Wu, et al.. (2023). Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.. Journal of Clinical Oncology. 41(16_suppl). 9003–9003. 4 indexed citations

15.

Xu, Yanjun, Zhiyu Huang, Jianhua Chang, et al.. (2023). Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study. Lung Cancer. 183. 107288–107288. 2 indexed citations

16.

Fu, Xinyu, et al.. (2023). Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study. Lung Cancer. 184. 107346–107346. 3 indexed citations

17.

Marathe, Omkar, Ying Cheng, Alexander I. Spira, et al.. (2023). 689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study. Annals of Oncology. 34. S480–S480.

18.

Pi, Wenhu, et al.. (2022). Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer. Analytical Cellular Pathology. 2022. 1–9. 6 indexed citations

19.

Song, Zhengbo, Dongqing Lv, Shiqing Chen, et al.. (2021). Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. Clinical Cancer Research. 28(3). 461–467. 31 indexed citations

20.

Zheng, Jing, He Cao, Yuping Li, et al.. (2020). Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study. Lung Cancer. 147. 130–136. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact